Market Overview

Benzinga's Top Pre-Market Losers

Share:
Related GILD
Japan's Ministry of Health, Labour and Welfare Approves Gilead's Harvoni
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide
Why Beating The S&P 500 Is So Hard, And Why Even Protecting Against A 10-15% Correction Matters (Seeking Alpha)
Related CROX
Wunderlich's Social Media Survey: Crocs Revamped Look, Taylor Swift Drives Excitement For Keds, And More
Benzinga's Top Initiations

Gilead Sciences (NASDAQ: GILD) dipped 2.40% to $58.66 in the pre-market session. Gilead Sciences shares have jumped 124.40% over the past 52 weeks, while the S&P 500 index has gained 25.09% in the same period.

Crocs (NASDAQ: CROX) shares fell 2.09% to $16.40 in the pre-market trading after Wedbush downgraded the stock from “outperform” to “neutral.”

Broadcom (NASDAQ: BRCM) shares dropped 1.45% to $33.20 in pre-market trading. Broadcom's trailing-twelve-month ROA is 4.58%.

Honeywell International (NYSE: HON) dipped 0.49% to $83.16 in the pre-market session after Nomura downgraded the stock from “buy” to “neutral.”

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Related Articles (BRCM + CROX)

Around the Web, We're Loving...

Get Benzinga's Newsletters